TSRO - Tesaro, Inc.

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD

Tesaro, Inc.

1000 Winter Street
Waltham, MA 02451
United States
339-970-0900
http://www.tesarobio.com

SectorHealthcare
SectorBiotechnology
Empleados a tiempo completo715

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Leon O. Moulder Jr.Co-Founder, CEO & Director1,09MN/A1957
Dr. Mary Lynne HedleyCo-Founder, Pres, COO & Director1,01MN/A1963
Mr. Timothy R. PearsonExec. VP & CFO646,76kN/A1968
Dr. Martin H. Huber Jr.Sr. VP & Chief Medical Officer732,52kN/A1960
Mr. Orlando OliveiraSr. VP & GM of InternationalN/AN/A1976
Los importes son a partir de 31 de diciembre de 2016 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Tesaro, Inc., a día 1 de junio de 2018, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 2; Derechos de los accionistas: 3; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.
Al usar Yahoo aceptas que Yahoo y sus socios puedan utilizar cookies para personalización y otros fines